Arkolith/Insider Trading/PHIO/Form 4

Bitterman Robert J

Chairman, Pres. & CEO, DirectorPhio Pharmaceuticals Corp. (PHIO) · full profile →Form 4 · filed Nov 24, 2025
Net Buying
Open-Market Buys
$6K
Open-Market Sells
$0
Net Open-Market Flow
$6K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Nov 21, 2025Buy(P)5K$1.14$6K281K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001683168-25-008639) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML